European Society of Endocrinology

Prevalence and accurate diagnosis of polycystic ovary syndrome in adolescents across world regions: a systematic review and meta-analysis Authors Adriana C H Neven, Maria Forslund, Sanjeeva Ranashinha, Aya Mousa, Chau Thien Tay, Alexia Peña, Sharon Oberfield, Selma Witchel, Helena Teede, Jacqueline A Boyle EJE Volume 191, Issue 4, October 2024 Open access paper 👉 https://lnkd.in/eTZEkqBh Abstract Objectives To examine the global prevalence of polycystic ovary syndrome (PCOS) among adolescents across world regions, comparing the 2003 Rotterdam consensus criteria with the current International Evidence-based PCOS Guideline criteria which omits polycystic ovarian morphology (PCOM). Design Systematic review and meta-analysis, Prospero CRD42022372029. Methods OVID MEDLINE, All EBM, PsycInfo, EMBASE, and CINAHL were searched from 1990 to November 2023 for studies assessing the prevalence of PCOS in unselected adolescent populations. Results Overall, 15 708 articles were identified. After removal of duplicates, 11 868 titles and abstracts and 445 full texts were assessed. Of these, 24 articles reporting on 23 studies from five world regions were included. In meta-analysis of 20 studies (n = 14 010 adolescents), global prevalence was 9.8% (95% CI 7.2, 12.3) according to original Rotterdam criteria, and 6.3% (95% CI 3.9, 8.8) according to International Evidence-based Guideline criteria. Global PCOS prevalence based on self-report was 9.8% (95% CI 5.5, 14.1). Grouped by WHO region, prevalence ranged from 2.9% (95% CI 2.0, 3.9) in the Western Pacific region to 11.4% (95% CI 7.1, 15.7) in the South-East Asia region according to guideline criteria. Conclusion This paramount global meta-analysis on adolescent PCOS diagnosis directly informed the 2023 International PCOS Guideline. Guideline criteria generated a global PCOS prevalence of 6.3%, compared with 9.8% on Rotterdam criteria (including PCOM). Excluding PCOM, which overlaps with normal pubertal transition, is expected to deter over-diagnosis. To avoid under-diagnosis, the Guideline recommends identifying those with either irregular cycles or hyperandrogenism as being “at risk”; this group should undergo longitudinal serial evaluations until adulthood. EJE Volume 191, Issue 4, October 2024 Read the open access paper 👉 https://lnkd.in/eTZEkqBh #PCOS #hyperandrogenism

🚨Late-breaking abstract submissions for #SfEBES2025 are now open!🚨 Have recent findings to share? This is your final opportunity to present at the UK’s largest #endocrinology conference, 10-12 March 2025 in Harrogate. Submit by 16 December 2024 to: ⭐Publish your work in Endocrine Abstracts. ⭐Connect with experts and peers. ⭐Contribute to advancements in research and patient care. ⭐Share your latest work and make an impact. Submit now 🔗https://ow.ly/eCc050UbFfG

Calling patients with adrenal insufficiency! This webinar is only a week away so sign up today! Join clinical experts and patients from across Europe for our first ESE Adrenal Patient Forum webinar on ‘Adrenal Insufficiency: daily living and adrenal crisis prevention’. 📅 Saturday 30 November 2024, 10:00-13:00 CET This webinar will be in English with simultaneous translations into French, German and Italian. 👉Register today for free! #AdrenalInsufficiency #PatientForum #Endocrinology #AdrenalHealth https://ow.ly/eJpf50Tmrlj

Nominations are now open for the 2026 ESE Awards! Help us to celebrate the achievements of #OurEndocrineCommunity and nominate yourself, or a colleague, for an ESE Award today. There are six ESE Awards now open for nomination - take a look and feel inspired by our 2025 prize winners. 📅 Nomination deadline: 28 February 2025 👉Nominate today! https://ow.ly/2Ob550UbTrK

European Society for Paediatric Endocrinology (ESPE) and ESE are delighted to have set up the JointEndo company to run shared activities including the ESPE-ESE 2025 Congress. The Directors had their second meeting at the ESPE Annual Meeting (#ESPE2024) in Liverpool earlier this week. We look forward to working together to bring paediatric and adult endocrinology even closer together! L-R: Helen Gregson, Mohamad Maghnie, Rasa Verkauskiene, Jérôme Bertherat, ESE President, Anita Hokken-Koelega, ESPE President, Mehul Dattani. (Djuro Macut and Wiebke Arlt were unable to attend.)

Invited review: Diagnosis and management of pituitary adenomas in children and adolescents Authors Dominique Maiter, Philippe Chanson, Stefan Matei Constantinescu, Agnès Linglart Abstract Background Pituitary adenomas (PAs)—also now called pituitary neuroendocrine tumours or Pit-NETS—are rare in children and adolescents and exceptional below the age of 10. Most evidence-based high-quality data are derived from larger studies in adult patients. Aims We will review recent knowledge on the epidemiology, clinical features, diagnosis, and treatment modalities of the different types of pituitary adenomas diagnosed in children and adolescents, emphasizing the many reasons why these cases should be discussed within pituitary-specific multidisciplinary teams with experts from both paediatric and adult practice. Conclusions Paediatric PA presents multiple peculiarities that may challenge their adequate management. They are overall proportionally larger and more aggressive than in adults, with potential mass effects including hypopituitarism. Hormonal hypersecretion is frequent, resulting in clinical syndromes affecting normal growth and pubertal development. Prolactinomas represent the most frequent subtype of PA found during childhood, followed by adrenocorticotropin (ACTH) and growth hormone (GH)–secreting adenomas, while clinically non-functioning adenomas are exceptionally diagnosed before the age of 16. The occurrence of a pituitary tumour in a young individual should also prompt genetic testing in each case, searching for either germline mutations in one of the known genes that may drive inherited/familial PA (such as the multiple endocrine neoplasia type 1 or MEN1 gene, or the aryl hydrocarbon receptor interacting protein or AIP gene), or for a mosaic activating mutation of GNAS as found in the McCune-Albright syndrome. EJE Volume 191, Issue 4, October 2024 Full paper 👉 https://lnkd.in/ezsF97nk ESE Members free access via 👉 https://lnkd.in/ep48a8bR #NETs #cushings #pituitary #endocrinology #pituitaryadenomas #LetsTalkAboutNETs #acromegaly

Huge congratulations to our prize winners at #EuroPit2024! Bara Dis Benediktsdotti, Svenja Leibnitz, Mathias Dottermusch, Suleyman Nahit Sendur, Prishila Fookeerah, Aleksandra Zdrojowy-Welna and Ivana Dora Vodanovic. #Endocrinology #PituitaryResearch

We are delighted to announce that the Jens Sandahl Christiansen Award winners for 2025 are Ana Djordjevic (Serbia) for Basic Science and Alessandro Prete (United Kingdom) for Clinical Science. The Jens Sandahl Christiansen Award is presented to endocrinologists for a specific piece of research or project which contributes to our understanding of metabolism. Ana Djordjevic has demonstrated exceptional commitment to research and has published three book chapters and over 60 scientific papers in international journals, giving her an excellent publication score. Ana is a Principal Research Fellow at the Institute for Biological Research Siniša Stanković (IBSS Institut za biološka istraživanja "Siniša Stanković" - Institut od nacionalnog značaja za Rep.Srbiju) at the University of Belgrade. She received her PhD from the University of Belgrade - Faculty of Biology in 2010, where she completed her undergraduate studies in Molecular Biology and Physiology. She is the head of the Department of Biochemistry at IBISS, and has participated in several national and international projects, most recently in the Twinning project STRIMHealth. Ana is currently Principal Investigator of a proof-of-concept project, Probiotic bacteria for reducing liver steatosis, funded by the World Bank SAIGE project. Ana’s early research focused on stress biology, and over the last 10 years, her research has remained in the field of molecular endocrinology but has focused mainly on diet-induced metabolic disorders, particularly type 2 diabetes and obesity. She is currently the Vice President of the Serbian Society for Molecular Biology (MolBioS). Alessandro Prete has an excellent publication record and must be commended for his focused and potentially impactful clinical research project. Alessandro is a Clinical Associate Professor of Endocrinology at the Department of Metabolism and Systems Science, University of Birmingham, UK. He obtained his PhD from the same University in 2022 and is also a Consultant Endocrinologist at the Queen Elizabeth Hospital NHS Trust Birmingham, UK. His area of research focuses on functioning adrenal tumours, endocrine hypertension, and adrenal insufficiency, combining clinical trials and experimental medicine studies. As well as receiving awards at both national and international conferences for his work, Alessandro has over 40 peer-reviewed publications. Find out more about the 2025 ESE Award Winners: https://ow.ly/z96y50UaTMh The 2025 ESE Awards will be presented at the Joint Congress of ESPE and ESE 2025. Ana will present a plenary lecture titled: 'Importance of gut microbiota for the effectiveness of weight loss – role of glucocorticoids’; and Alessandro will present a plenary lecture titled, 'Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors: A Cross-Sectional Multicenter Study’. Register your interest: https://ow.ly/pkUC50UaTMj Submit your abstract: https://ow.ly/kGGn50UaTMk We hope you can join us.

It's the third and final day of EuroPit 2024 in Annecy, France - we have had a great few days of learning, collaborating and networking with our colleagues from across Europe. We thank everyone who attended, and all the speakers and organisers who contributed to this special event. #OurEndocrineCommunity #endocrinology

We thank everyone who visited the Joint Congress 2025 booth at #ESPE2024. ESPE President Anita Hokken-Koelega and ESE President Jérôme Bertherat hope to see you all again in Copenhagen next May. https://ow.ly/3KRM50U9SlF #ConnectingEndocrinology2025